Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
Carolin Victoria SchneiderKai Markus SchneiderAnastasia RaptisHelen HuangChristian TrautweinStephen CaldwellPublished in: Alimentary pharmacology & therapeutics (2024)
MASLD is prevalent among patients with elevated PDFF on MRI. There are different sex- and BMI-specific prevalence of different steatotic liver disorders. At-risk MASH demonstrates the most severe metabolic and inflammatory profiles. This study provides novel estimates for the at-risk MASH population that will be eligible for treatment with pharmacologic therapy when approved by regulatory authorities.